NCT03213678 2026-04-21Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Completed18 enrolled 12 charts